INTRODUCTION
The enzymic machinery involved in the blood-coagulation process is controlled by a number of positive-and negative-feedback systems. As a result, blood coagulation is a system that, on the one hand, responds rapidly to small triggering signals and, on the other hand, is rapidly shut down so that it does not propagate beyond the site of injury. The key steps in the regulation of this process are the activation and inactivation of membrane-bound proteins which function as essential cofactors of membranebound enzymes, e.g. activation of factors V and VIII by thrombin and their inactivation by activated protein C (for a review see [1] ).
The enzymic complex that consists of the cofactor tissue factor (TF, an integral membrane glycoprotein) and the serine protease factor Vlla is thought to be the major initiator of the bloodcoagulation process in vivo [2] . The neutralization of the enzymic activity of this complex by tissue factor pathway inhibitor (TFPI), a 42 kDa glycoprotein consisting of three tandem Kunitz-type inhibitor domains, a negatively charged N-terminus and a positively charged C-terminus [3] , is assumed to cause an essential shift in the coagulation pathways [4] [5] [6] . That is, an initial burst of TF-factor VIla-dependent factor Xa generation is turned off by TFPI, and is then followed by a maintenance dose of factor Xa produced by the classic 'intrinsic' pathway. Factor Xa seems to play an essential role in shutting off its own generation [7] [8] [9] , because the inhibition of the TF/VIIa activity by plasma concentrations of TFPI is only significant when factor Xa is also present. The final product of the inhibition reaction is a dissociable quaternary Xa/TFPI/VIIa/TF complex [5] .
In order to understand the importance of this regulatory process and the potential therapeutic role of TFPI as an anticoagulant drug, knowledge of the kinetics of the formation of the quaternary complex is essential. It emerged from studies reported so far that the ability of TFPI to inhibit TF/VIIainduced coagulation seems to depend on the rate of association (k.n) and dissociation (kIc,) were (5.1 +0.7) x 106 M-1 s-. and (2.6 + 0.9) x 10-4 s-I respectively. Thus, although the inhibition constant (50 pM) is far below the plasma concentration (2.5 nM) of TFPI, the half-time for transition to equilibrium in plasma is rather long (66 s). The truncated forms of TFPI differ in that they have a 4-fold lower kon value but a similar dissociation rate constant. Therefore the inhibition constant, K1, is 4-fold higher (0.2 nM) and the half-time to achieve equilibrium is prolonged to 250 s. The kon values of full-length and C-terminal-truncated TFPI, but not that of TFPI 1161, were found to decrease with increasing ionic strength.
between factor Xa and TFPI, the first step in the formation of the inactive Xa/TFPI/VIIa/TF complex [10, 11] . It has been postulated that TFPI is a slow, tight-binding, competitive and reversible inhibitor of factor Xa [5] , but so far no data have been reported on the association and dissociation rate constants. In this paper we report on the rates of association and dissociation of complex-formation between human factor Xa and TFPI. We have examined three variants of recombinant TFPI, namely fulllength TFPI, the C-terminal truncated TFPI lacking the highly basic sequence of residues 254-265, and TFPI truncated between the second and third Kunitz domains (TFPI1 161). The role of the basic C-terminus in the interaction between factor Xa and TFPI was also examined by varying the ionic strength.
EXPERIMENTAL Materials
The chromogenic substrate for factor Xa, methoxycarbonyl-Dcyclohexylglycyl-glycyl-arginine p-nitroanilide (Spectrozyme FXa) was from Pentapharm (Basel, Switzerland). BSA (fattyacid-free) was purchased from Sigma (St. Louis, Mo, U.S.A.). All reactions were carried out at 37°C in 50 mM Tris/HCl, containing 175 mM NaCl and 0.5 mg of BSA/ml, pH 7.9 (TBSA).
Proteins
The human coagulation factor Xa was purified to homogeneity and quantified as previously described [12] . The recombinant TFPI preparations were kindly supplied by Dr. Ole Nordfang (Novo Nordisk, Gentofte, Denmark). Full-length recombinant human TFPI (FL-TFPI) and the C-terminal-truncated variant of TFPI lacking the C-terminal basic region were obtained from transfected baby-hamster kidney cells as described previously [13] and were separated by cation-exchange chromatography [10] . The preparation of truncated TFPI consisted of a mixture Abbreviations used: TF, tissue factor; TFPI, tissue factor pathway inhibitor; TFPI1-161, recombinant C-terminal-truncated TFPI containing residues 1-161; TBSA, 50 mM Tris/HCI (pH 7.9) containing 175 mM NaCI and 0.5 mg of BSA/ml; pNA, p-nitroanilide.
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T. Lindhout and others of variants ending at amino acids Ile-247, Ser-248, Gly-250 and Thr-255 [10] . The C-terminal-truncated variant of TFPI lacking the third Kunitz-type domain and the C-terminal region (TFPII1,61) was expressed in Saccharomyces cerevisiae and purified as described previously [14] . Data from progress curves in the absence of TFPI were fitted to the following equation: (4) Since no inhibitor of factor Xa was added, the pseudo-first-order rate constant k reflects non-specific loss of factor Xa activity.
When preincubated mixtures of factor Xa and TFPI were added to a solution containing the substrate for factor Xa, the initial concentration of the factor Xa-TFPI complex (El) in the cuvette is given by eqn. (5): 
RESULTS
Inhibition kinetics as derived from progress curves stated with factor Xa The kinetics of factor Xa-TFPI complex-formation were derived from progress curves of factor Xa-catalysed pNA formation in the presence of TFPI. The factor Xa concentrations and those of the recombinant TFPI variants used in these experiments were chosen such that the progress curves of product formation revealed both the progress of inhibition and the steady-state velocity. Consequently, the TFPI concentration had to be chosen rather close to the factor Xa concentration, causing a significant depletion of free TFPI during the course of the reaction. The rather long duration of the experiments also caused in some cases a significant depletion of substrate. In our analysis, however, we corrected for both the depletion of substrate and free inhibitor (see the Experimental section; cf. eqns. 2 and 3, respectively). These equations cannot be solved in closed form, and therefore a numerical solution was used to analyse the experimental data.
A representative example of a plot of pNA versus time for the factor Xa-catalysed reaction in the absence of TFPI (curve a) is shown in Figure 1 . The simulated curve a', obtained by fitting eqns. (2) and (3) (2) and (3), is superimposed on the experimental curve. Again, the residuals of the observed minus simulated data were very small (less than 0.02,M) and varying around zero. The standard errors of the estimated rate constant of association (kon), the rate constant of dissociation (koff) and the catalytic rate constant of the factor Xa-substrate reaction (kcat.) were less than 0.1 % of the value. Thus the progress curves in the presence of TFPI are also adequately described by the model.
We next verified our assumption that the peptidyl substrate competes with TFPI for the active site of factor Xa. Progress curves were performed in the presence of a variety of substrate concentrations (100-900 /LM). The reactions were started by the addition of factor Xa (0.25 nM), and after 2 min C-terminaltruncated TFPI (1 nM) was added. The progress curves in the presence of TFPI were fitted to eqns. (2) 10-fold dilution of the preincubated mixture into a cuvette containing the peptidyl substrate. A typical example of a progress curve of the recovery of factor Xa activity is shown in Figure 3 . The data from the progress curves were fitted to the differential equations (2) and (3) (Tables 1 and   2 ). This agreement between kinetic and equilibrium data again reinforces our conclusion that the simplified model allows an adequate description of the experimental data.
Effect of ionic strength on the factor Xa-TFPI inhibitory reaction Among the three different forms of TFPI, the full-length TFPI showed the highest kon and lowest K1 value in the interaction with human factor Xa. Since only the full-length TFPI contains a highly positively charged C-terminus, it was expected that electrostatic interactions between factor Xa and TFPI determines to some extent the binding kinetics. We therefore examined the effect of ionic strength (I) of the reaction medium on the kinetic constants, kon and KM of the reaction of factor Xa with the three recombinant forms of TFPI.
We first determined at each ionic strength the kcat and Km values of the reaction between factor Xa and the peptidyl substrate Spectrozyme FXa. We found that the Km varied from 150 prM at I = 0.1 to 400 ,tM at I = 0.4. The I had no effect on the kcat* Progress curves in the presence of a fixed amount of TFPI were then performed in TBSA buffer containing varying amounts of NaCl. The value of Km as determined at each I value was held fixed at this value for the analysis of the progress-curve data according to eqns. (2) and (3) . Figure 4 shows the effect of I on the kinetic constants of the reactions between factor Xa and full-length TFPI, C-terminal-truncated TFPI and TFPI, 161. The kon values were corrected for substrate competition by application of the expression k1n = k0 aPP (1 + S/Km). The standard errors of the estimates were less than 1 % of the value. It is apparent that I hardly affected the binding kinetics of TFPIl-161 to human factor Xa. Interestingly, the C-terminal-truncated TFPI showed the strongest dependency on I in its reaction with factor Xa. Moreover, the differences between truncated TFPI and fulllength TFPI with respect to their kon values almost disappeared at low I.
DISCUSSION
The much higher anticoagulant activity of full-length TFPI, as compared with a C-terminal-truncated TFPI, is attributed to a C-terminal-mediated inhibitory activity of the full-length TFPI against factor Xa [10, 1 1] . However, no differences were detected between the two forms of TFPI in the initial rates of tissue factor/factor Vlla-catalysed factor X activation in a buffer system [11] . To understand the structure-function relationships, it thus becomes increasingly important to derive the kinetic constants of the factor Xa-TFPI reaction on the basis of an appropriate kinetic model of that interaction.
We based our kinetic model on the assumption that the association process between factor Xa and the different recombinant forms of TFPI is a reversible bimolecular reaction (Scheme 1). It is very likely that we over-simplified the mechanism of action of the inhibitor. Laskowski and Kato [18] proposed a standard mechanism of action of Kunitz-type inhibitors in which the stable protease-inhibitor complex is preceded by a loose preequilibrium complex. Consequently, in the latter case the estimated kinetic constants obtained with the model as depicted in Scheme 1 describe the overall process of inhibition, including all steps before equilibrium is attained.
Three different approaches were used to generate the data from which the association rate constants (kon) and disssociation rate constants (koff) as well as the inhibition constant, K1, were obtained: (1) the formation of the inactive factor Xa-TFPI complex was monitored by continuous measurement of the changes in the rate of pNA formation, (2) the rate of pNA formation was continuously monitored after preincubating factor Xa with TFPI in the absence of substrate and diluting the factor Xa-TFPI complex into a reaction mixture containing the peptidyl substrate, and (3) the residual factor Xa activity after preincubating factor Xa and TFPI was measured from the initial rate of pNA formation after the addition of peptidyl substrate to the reaction mixture. The present data show that the different experimental settings yielded virtually identical values for the rate constants kon and koff (Tables 1 and 2 ). In addition, the K1 values calculated from the rate constants were comparable with those determined from equilibrium experiments. The data thus strongly indicated that the kinetics of the TFPI-factor Xa reaction could be adequately described by Scheme 1. Our observation that the estimated kcat value did not vary significantly with the TFPI concentration (Tables 1 and 2 ) is also consistent with a mechanism of inhibition in which factor Xa and TFPI slowly interact. However, it should be pointed out that these observations did not exclude a two-step mechanism. We wish to emphasize that the time-dependence of the reaction between factor Xa and the TFPI variants was such that at TFPI concentrations higher than 1 nM for fulllength TFPI, and higher than 2 nM for C-terminal-truncated not vary with the substrate concentration ( Figure 3) . However, the extent of dissociation is affected by a competing substrate;
Ki (app.) increased with substrate concentration.
The average kon and koff values ( + S.D.) of the different forms of TFPI calculated from the data shown in Tables 1 and 2 are summarized in Table 3 . The rate constant of association of fulllength TFPI is about 4 times the rate constants of association found for C-terminal-truncated TFPI and TFP11161. Apparently, the positively charged C-terminal region of TFPI is involved in the association process with factor Xa, which then points to an ionic interaction being important in the binding of full-length TFPI to factor Xa. Our data on the association kinetics as obtained at different ionic strength, however, suggest that ionic interaction is also important in the reaction between C-terminaltruncated TFPI and factor Xa. (Table 3) respectively. However, when we take into account a 1000-fold difference in plasma concentration, antithrombin III (even in the absence of heparin) becomes as important as TFPI as a factor Xa inhibitor (under the assumption that depletion of TFPI does not occur). That is, the half-lifetime of factor Xa activity in plasma is 84 s [20] and that of factor Xa in the presence of 2 nM of the native full-length TFPI is 66 s (Table 3 ). Therefore, it may not be excluded that TFPI, in addition to its specific function in inhibiting tissue-factor-dependent factor Xa generation, also acts as a physiologically important inhibitor of factor Xa.
As yet, it remains to be seen whether the kinetic data of the bimolecular reaction between TFPI and factor Xa reflect the kinetics of the inhibitory reaction between TFPI and TF/factor Vlla-catalysed factor Xa generation. If so, then one could speculate that TFPI is a rather inefficient inhibitor, because, due to its relative long half-time of complex-formation with factor Xa (66 s) and the high catalytic efficiency of the initiator of blood coagulation (TF/factor Vlla), a large amount of factor Xa can be produced before the activator is neutralized.
